科济药业(02171)在最近两个交易日内股价表现引发了市场的广泛关注,股价累计大涨超过80%。这一暴涨行情的主要推手是公司旗下新型免疫细胞疗法产品CT0590在最新临床试验中取得令人鼓舞的数据。
据公司此前披露,CT0590是科济药业研发的针对多发性骨髓瘤等难治性血液肿瘤的通用型CAR-T细胞疗法。在首个人体一期试验中,5名受试者中有3例患者获得了缓解反应,其中2例达到了严格完全缓解,1例达到部分缓解。值得关注的是,部分患者的缓解状态持续达20多个月之久。同时,该疗法的整体安全性可控。
此番亮眼的临床试验数据引发了投资者对CT0590未来上市销售前景的乐观预期。作为一种针对多发性骨髓瘤等难治性血液肿瘤的新型疗法,CT0590如果顺利上市将为相关患者带来新的治疗选择。这为科济药业在免疫细胞疗法等创新药领域的长期发展奠定了雄厚基础,推升了市场对公司前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.